Healthcare Industry News: PASCAL Photocoagulator
News Release - July 12, 2007
OptiMedica(R) and Topcon Europe Medical(R) Sign Distribution AgreementPASCAL Photocoagulator is Now Widely Available in Europe
SANTA CLARA, Calif. and Capelle a/d IJssel, Netherlands, July 12 (HSMN NewsFeed) -- The OptiMedica ® Corporation, a privately held developer of ophthalmic technologies focused on treating vision-threatening diseases, and Topcon Europe Medical B.V.®,the European subsidiary of the Topcon Corporation, a world leader in the manufacturing of optical and electronic instruments, announced today an agreement in which Topcon Europe Medical will become the exclusive distributor of the Pascal® Photocoagulator, in key European markets. "This collaboration will enable ophthalmologists throughout Europe to acquire the PASCAL Photocoagulator along with Topcon's superb diagnostic instrumentation," said Jean-Robert Strele, Vice President of International Business at OptiMedica. "Given the great demand for the PASCAL Photocoagulator in international markets, we are delighted to partner with Topcon. It has an outstanding reputation in ophthalmology and a demonstrated commitment to excellence in customer service.
"Adding the PASCAL Photocoagulator to our portfolio of outstanding products, which includes the new 3D OCT-1000 and IMAGEnet, will allow us to better meet the needs of the European ophthalmic community," said Eric Franken, Director of Topcon Europe Medical.
OptiMedica Corp. develops and markets performance driven ophthalmic technologies focused on improving patient outcomes. OptiMedica holds the exclusive license to the PASCAL® (PAttern SCAn Laser) method of photocoagulation and its associated technologies. OptiMedica was founded in 2004 in Santa Clara, Calif. and is funded by Kleiner, Perkins, Caufield & Byers and Alloy Ventures. For more information, please visit http://www.optimedica.com.
About the PASCAL Photocoagulator
The PASCAL (Pattern Scan Laser) Photocoagulator is designed to optimize the treatment of eye diseases by applying a predetermined pattern array of up to 56 laser spots to the retina within 0.6 seconds. These laser pulses are delivered in a rapid sequence, resulting in improved precision, safety, patient comfort and a significant reduction in treatment time compared with single-spot photocoagulation.
About Topcon Europe Medical
Topcon Europe Medical B.V. is located near Rotterdam, in Capelle a/d IJssel, The Netherlands. Topcon Europe Medical is the European Eye care Business Unit headquarters of the Topcon Corporation, a Japanese Multinational company that celebrated its 75 year anniversary this year. Topcon Corporation is a world leader in the design and development of optical and electronic instruments for medical, ophthalmic, surveying, construction and machine control industries. Topcon Europe Medical has an extensive network of distributors throughout Europe with its own subsidiaries and branch offices in Denmark, France, Germany, Ireland, Italy, Poland, Spain, Sweden and the United Kingdom.
Source: OptiMedica Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.